| Presentation preference | Oral presentation |
| Title | The efficacy of adalimumab in treating patients with central multifocal choroiditis |
| Purpose | To evaluate the efficacy of adalimumab (ADA) in patients with central multifocal choroiditis (cMFC) refractory to conventional corticosteroid-sparing immunomodulatory agents (IMT). |
| Methods | Medical records were reviewed from all patients with cMFC and treated with ADA with follow-up of at least 12 months. The study focused on the 12 months prior to and after the start of ADA. The imaging results were independently evaluated by two ophthalmologists. The main outcomes were the number of patients without a relapse of disease activity in 12 months after the start of ADA and the ability to stop the systemic corticosteroids. |
| Results | Twelve patients (18 eyes) were included. In 8/12 (67%) patients no relapse of disease activity was observed in the 12 months after the start of ADA. In 9/12 patients the systemic corticosteroid treatment could be stopped and in an additional 2 patients tapered to ≤7,5mg daily. In the 12 months before the start of ADA, the patients experienced a median of 2 (range 1-3) relapses of disease activity. Nine patients experienced relapses while treated with a combination of systemic corticosteroids (mean dose 13,6 mg range 5-25 mg) and IMT. Moreover, 3 patients treated with IMT, experienced relapses after tapering and stopping the systemic corticosteroids. In the 5 eyes with CNV before the start of ADA, the anti-VEGF injections could be stopped after the start of ADA. |
| Conclusion | ADA may be effective in patients with cMFC refractory to IMT and may be considered as a treatment option. |
| Conflict of interest | Yes |
| Details of conflicting interests | JH has received a grant from abbvie to conduct a research regarding the efficacy of adalimumab in children with noninfectious uveitis. The following authors have no financial disclosures: EL, J, L, NH. |
Authors 1
| Last name | DE GROOT |
| Initials of first name(s) | E.L. |
| Department | Ophthalmology |
| City | Utrecht |
| Country | Netherlands |
Authors 2
| Last name | Ossewaarde-van Norel |
| Initials of first name(s) | J. |
| Department | Ophthalmology |
| City | Utrecht |
| Country | Netherlands |
Authors 3
| Last name | Ho |
| Initials of first name(s) | L. |
| Department | Ophthalmology |
| City | Utrecht |
| Country | Netherlands |
Authors 4
| Last name | ten Dam-van Loon |
| Initials of first name(s) | N.H. |
| Department | Ophthalmology |
| City | Utrecht |
| Country | Netherlands |
Authors 5
| Last name | de Boer |
| Initials of first name(s) | J.H. |
| Department | Ophthalmology |
| City | Utrecht |
| Country | Netherlands |
